This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

INVEGA® SUSTENNA® Three-Month Formulation Of Paliperidone Palmitate Enters Phase 3 Clinical Program For Schizophrenia

Alkermes plc (NASDAQ: ALKS) today announced that Janssen Research & Development, LLC has initiated a phase 3 clinical research program for a three-month formulation of INVEGA ® SUSTENNA ® (paliperidone palmitate), an injectable medicine for the treatment of schizophrenia. The investigational product is being developed by Janssen Pharmaceutica, NV, licensee to Alkermes’ proprietary technology for nanoparticles. Two phase 3 studies are expected to enroll approximately 1,800 patients with schizophrenia and will assess the efficacy, safety and tolerability of the three-month injectable formulation. These clinical studies are expected to be completed in the second half of calendar 2014.

“The development of a three-month formulation of INVEGA SUSTENNA represents a first for the field of atypical antipsychotics and builds on Alkermes’ expertise in long-acting technologies,” said Dr. Elliot Ehrich, Chief Medical Officer at Alkermes. “Patients and physicians have a keen interest in new treatment options for schizophrenia. A three-month formulation of a long-acting atypical antipsychotic could significantly advance the treatment paradigm for schizophrenia, and we are looking forward to seeing the results from these phase 3 studies of INVEGA SUSTENNA.”

INVEGA SUSTENNA was approved as a once-monthly injectable medication for schizophrenia in the U.S. in 2009. It was also approved in the EU in 2011, where it is available under the trade name XEPLION ®. INVEGA SUSTENNA is marketed worldwide by the Janssen Pharmaceutical Companies. INVEGA SUSTENNA incorporates Alkermes’ proprietary technology for nanoparticles, and Alkermes earns a royalty on worldwide sales of the product.

Phase 3 Program

Two phase 3 studies of the three-month formulation of INVEGA SUSTENNA have been initiated and are expected to enroll approximately 1,800 patients with schizophrenia.

The first study is a randomized, multicenter, double-blind, parallel-group, fixed-dose, relapse-prevention study and will explore the efficacy, safety and tolerability of the three-month formulation of INVEGA SUSTENNA, compared to placebo. Approximately 500 patients with schizophrenia will be enrolled in the study. The primary efficacy endpoint of the study is time to first relapse event during the double-blind phase.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs